Literature DB >> 22845716

PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget's disease.

Yue Qian1, Na Zhang, Siyuan Chen, Shujuan Chu, Aiping Feng, Houjun Liu.   

Abstract

BACKGROUND: Phosphatidylinositol 3-kinase (PI3K), Ras-related C3 botulinum toxin substrate 1 (Rac1) and P21-activated protein kinase 1 (PAK1) appear to play important roles in the pathogenesis of several tumors, but their expressions in extramammary Paget's disease (EMPD) have not been investigated yet.
OBJECTIVES: To investigate the potential contribution of the PI3K, Rac1 and PAK1 to the development of EMPD.
METHODS: Thirty-five paraffin-embedded EMPD specimens were subjected to immunohistochemical staining for PI3K (85α), Rac1 and pPAK1.
RESULTS: All the 35 primary EMPD specimens, including 20 non-invasive EMPD, 13 invasive EMPD and 2 metastatic lymph nodes, showed cytoplasm overexpression of PI3K (85α), Rac1 and pPAK1. The expression (% positive cells) of PI3K(85α), Rac1 and pPAK1 (90.1 ± 8.6, 91.4 ± 9.5 and 89.6 ± 10.8% ) in EMPD were significantly higher than in apocrine glands of normal skin ( 20.1 ± 11.9, 29.8 ± 8.9, 41.1 ± 13.4%), and the expression in invasive EMPD with lymph node metastasis (98.2 ± 1.7, 98.8 ± 0.7 and 98.4 ± 0.9%) are significantly higher than in invasive EMPD without lymph node metastasis (94.1 ± 2.6, 96.5 ± 1.7 and 95.3 ± 1.1%) and non-invasive EMPD (85.2 ± 8.4, 87.1 ± 9.9 and 83.1 ± 10.6%). There were significant positive correlations of the expression levels between PI3K (85α) and Rac1, as well as between Rac1 and pPAK1 in EMPD.
CONCLUSIONS: These results indicate that PI3K, Rac1 and PAK1 may play important roles in the pathogenesis of EMPD.
Copyright © 2012 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22845716     DOI: 10.1111/j.1600-0560.2012.01973.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  1 in total

Review 1.  Prognostic Factors of Extramammary Paget's Disease.

Authors:  Naohito Hatta
Journal:  Curr Treat Options Oncol       Date:  2018-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.